Search results
Results from the WOW.Com Content Network
Common anti-arrhythmic drugs under the modernized classification according to Lei et al. 2018 A recent publication (2018) has now emerged with a fully modernised drug classification. [ 24 ] This preserves the simplicity of the original Vaughan Williams framework while capturing subsequent discoveries of sarcolemmal, sarcoplasmic reticular and ...
Sotalol is indicated for the treatment of atrial or ventricular tachyarrhythmias, and AV re-entrant arrhythmias. Ibutilide is the only antiarrhythmic agent currently approved by the Food and Drug Administration for acute conversion of atrial fibrillation to sinus rhythm.
Flecainide is a medication used to prevent and treat abnormally fast heart rates. [1] This includes ventricular and supraventricular tachycardias. [1] Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments. [1]
Azimilide is a class ΙΙΙ antiarrhythmic drug (used to control abnormal heart rhythms). The agents from this heterogeneous group have an effect on the repolarization, they prolong the duration of the action potential and the refractory period.
Bretylium (also bretylium tosylate) is an antiarrhythmic agent. [1] It blocks the release of noradrenaline from nerve terminals. In effect, it decreases output from the peripheral sympathetic nervous system.
Dronedarone has been termed a "multichannel blocker". [citation needed] However, it is unclear which channel(s) play a pivotal role in its success. [9]Thus, dronedarone's actions at the cellular level are controversial, with most studies suggesting an inhibition in multiple outward potassium currents including rapid delayed rectifier, slow delayed rectifier and ACh-activated inward rectifier. [10]
Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication used in the treatment of ventricular tachycardia. [2] It is a sodium channel blocker and is classified as a Class 1a anti-arrhythmic agent.
Procainamide works as an anti-arrhythmic agent and is used to treat cardiac arrhythmia. It induces rapid block of the batrachotoxin (BTX)-activated sodium channels of the heart muscle and acts as antagonist to long-gating closures. The block is voltage-dependent and can occur from both sides; either from the intracellular or the extracellular side.